Condition: Advanced Solid Tumours · Non-Small Cell Lung Cancer · Colorectal Cancer · Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of SIM0610 in subjects with locally advanced/metastatic solid tumors. Accelerated titration (ATD) and Bayesian optimal interval design (BOIN) will be used to guide dose escalation in part1, the preliminary anti-tumor effect of SIM0610 will to be further evaluated in part 2.
This description comes directly from the study's public registry record.
Jiawei Yao · +8618868816194 · yaojiawei@zaiming.com
Always discuss trial participation with your own doctor first.
| Chongqing Cancer Hospital | Chongqing, Chongqing Municipality, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| the First Hospital of China Medical University | Shenyang, Liaoning, China | Not Yet Recruiting |
| The Affiliated Cancer Hospital of Shandong First Medical University& Shan Dong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07348211